Journal of Clinical Investigation
hideThe Journal of Clinical Investigation (JCI or J Clin Invest) is a leading biomedical journal, with a 2008 impact factor of 16.559. The journal makes its research articles -- including access to articles back to 1924 -- freely available online.
The website of the journal describes it as "a premier venue for critical advances in biomedical research, authoritative reviews, and commentaries that place research articles in context." The first issue of the journal appeared in 1924, and within a few decades, it had established itself as a reputed journal for primary clinical research.
The JCI's Editorial Board is unique in that its members are located chiefly at a singular academic medical center and are predominantly members of the American Society for Clinical Investigation. The leadership of the Editorial Board changes every five years: As of March 2007, the Editorial Board is located at the University of Pennsylvania under the leadership of Laurence A. Turka, M.D. From March 2002 to March 2007, the Editorial Board was located at Columbia University under the leadership of Andrew Marks, M.D. Ushma S. Neill, formerly with Nature Medicine, is the journal's Executive Editor.
This monthly journal publishes original research and review articles, including periodic review series focusing on important topics in biomedicine.
For more information about Journal of Clinical Investigation, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
News tagged with journal of clinical investigation
Why Some Monkeys Don't Get AIDS
Medicine & Health / HIV & AIDS
Dec 03, 2009 |
not rated yet |
0
(PhysOrg.com) -- Two studies published this month in the Journal of Clinical Investigation provide a significant advance in understanding how some species of monkeys such as sooty mangabeys and African green ...
New understanding of how to prevent destruction of a tumor suppressor
Dec 07, 2009 |
not rated yet |
0
Researchers from the Indiana University School of Medicine and colleagues at the University of Texas Southwestern and Case Western University have determined how the protein Mdm2, which is elevated in late-stage ...
Scientists identify possible therapy target for aggressive cancer
Dec 01, 2009 |
5 / 5 (1) |
0
UT Southwestern Medical Center researchers have found that a naturally occurring protein -- transforming growth factor beta1 (TGF-ß1) -- which normally suppresses the growth of cancer cells, causes a rebound effect after ...
Tumors Feel the Deadly Sting of Nanobees
Nanotechnology / Bio & Medicine
Aug 28, 2009 |
4.8 / 5 (13) |
3
When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University ...
Ice cream may target the brain before your hips, study suggests
Sep 14, 2009 |
4.9 / 5 (8) |
2
Blame your brain for sabotaging your efforts to get back on track after splurging on an extra scoop of ice cream or that second burger during Friday night's football game.
New way to kill cancer found using body's immune system
Jul 21, 2009 |
5 / 5 (9) |
6
(PhysOrg.com) -- Scientists have discovered a new way of killing cancer cells in a breakthrough that could eventually lead to new treatments for a range of different cancers.
Death-inducing proteins key to complications of bone marrow transplantation
Dec 01, 2009 |
not rated yet |
0
Treatment for a number of cancers and other medical conditions is transplantation with bone marrow from a genetically nonidentical individual (a process known as allogeneic bone marrow transplantation [allo-BMT]).
Researchers find inflammation critical in aortic dissection
Nov 16, 2009 |
not rated yet |
0
The aorta, the body's largest artery, stretches from the chest to below the kidneys, expanding and contracting with the pressure of blood driven directly into it by the heart. Although its walls are extraordinarily strong, ...
Scientists discover cells that control inflammation in chronic disease
Nov 17, 2009 |
5 / 5 (2) |
0
(PhysOrg.com) -- A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time ...
Wistar researchers show targeting 'normal' cells in tumors slows growth
Nov 16, 2009 |
1 / 5 (1) |
0
Targeting the normal cells that surround cancer cells within and around a tumor is a strategy that could greatly increase the effectiveness of traditional anti-cancer treatments, say researchers at The Wistar Institute.
Experimental Approach May Reverse Rheumatoid Arthritis and Osteoporosis
Sep 21, 2009 |
4.8 / 5 (12) |
0
(PhysOrg.com) -- Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical In ...
Tumors feel the deadly sting of nanobees
Nanotechnology / Bio & Medicine
Aug 10, 2009 |
3.9 / 5 (7) |
0
(PhysOrg.com) -- When bees sting, they pump poison into their victims. Now the toxin in bee venom has been harnessed to kill tumor cells by researchers at Washington University School of Medicine in St. Louis. The researchers ...
Study provides first clear idea of how rare bone disease progresses
Nov 12, 2009 |
5 / 5 (1) |
0
An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ...
Trojan horse for ovarian cancer -- nanoparticles turn immune system soldiers against tumor cells
Nanotechnology / Bio & Medicine
Jul 15, 2009 |
5 / 5 (5) |
1
In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor.
Biology of flushing could renew niacin as cholesterol drug
Apr 06, 2009 |
4.8 / 5 (4) |
1
Deft molecular detective work at Duke University Medical Center suggests that scientists may soon be able to resurrect niacin as one of the best and cheapest ways to manage cholesterol.
